Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use RELEXXII® safely and effectively. See full prescribing information for RELEXXII®. RELEXXII® (methylphenidate hydrochloride extended-release tablets) for oral use, CII Initial U.S. Approval: 2000
Medication labelWhy this: Advisory · dailymed-prescription
RELEXXII is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults (up to the age of 65 years) and pediatric patients 6 years of age and older [see Clinical Studies (14)]. Limitations of Use The use of RELEXXII is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions (5.7), Use in Specific Populations (8.4)].
- generic_name
- methylphenidate hydrochloride
- product_names
- methylphenidate hydrochloride
- ndc
- 68025-088, 68025-088-30, 68025-089, 68025-089-30, 68025-095, 68025-095-10, 68025-095-30, 68025-096, 68025-096-10, 68025-096-30, 68025-097, 68025-097-10, 68025-097-30, 68025-084, 68025-084-30, 68025-098, 68025-098-10, 68025-098-30
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en